Browse studies

Find your next paid study

27,270 recruiting studies available now

Pembrolizumab and GVD With ctDNA-guided Consolidation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium

This is a single arm, open-label, multicenter, phase II study of pembrolizumab (pembro), gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) in patients …

Hodgkin Lymphoma, AdultRefractory Hodgkin LymphomaClassic Hodgkin Lymphoma

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Michael Spinner, MDNCT07021989

Observational

Post Marketing Data Collection on Use of ProSense® Cryoablation System With Adjuvant Endocrine Therapy for the Treatment of Patients With Low-Risk, Early-Stage Breast Cancer (ChoICE Trial)

The FDA has granted marketing authorization for the ProSense® Cryoablation System for the local treatment of patients aged 70 years or older with low-risk earl…

Low-Risk, Early Stage Breast Cancer

Estimated

~$10 – $1,050

Actual pay is set by the research site.

IceCure Medical Ltd.NCT07629206

Observational

Self-Concept Reinforcement for Early School Readiness: Pilot Randomized Controlled Trial of a Clinic-Based Intervention for Young African American Children

The goal of this pilot randomized controlled trial is to evaluate a self-concept intervention (Self-Concept Reinforcement for Early School Readiness (SCR4ESR))…

Child BehaviorChild Behavior ProblemChild Behavior Disorders

Estimated

~$10 – $750

Actual pay is set by the research site.

Children's Hospital Los AngelesNCT06084910

Phase 2

Ketamine for the Treatment of Opioid Use Disorder

The goal of this clinical trial is to learn if ketamine works to reduce craving for opioids in adults enrolled in methadone treatment for opioid use disorder. …

Opioid Use Disorder

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of Maryland, BaltimoreNCT06943859

Phase 2

A Randomized Phase II Trial of Sacituzumab Govitecan-HZIY (SG) and Bevacizumab Versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients With Platinum-Sensitive Ovarian Cancer That Has Progressed on Prior Maintenance PARP Inhibitor Therapy

This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizuma…

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid AdenocarcinomaRecurrent Platinum-Sensitive Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma+3 more

Estimated

~$75 – $1,800

Phase 3

A Phase 3, Multiregional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma (IGNITE)

The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therap…

Relapsed/Refractory Primary Central Nervous System Lymphoma

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Ono Pharmaceutical Co., Ltd.NCT07104032

Observational

Post Approval Effectiveness and Durability Evaluation of the Altaviva™ Tibial Device

The purpose of this prospective, multicenter study is to assess the long-term safety and effectiveness of the Altaviva™ system for the treatment of UUI

Urge Urinary Incontinence

Estimated

~$10 – $1,125

Actual pay is set by the research site.

MedtronicNeuroNCT07456865

Observational

Evaluation of Gixam's Efficacy Predicting the Presence of Advanced and Non-advanced Colorectal Neoplasia in a FIT Negative Population

The goal of this clinical trial is to learn if the Gixam device effectively identifies persons with pre-cancer or cancer in the colon and rectum in adults aged…

CRC ScreeningMicrobiome

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Jubaan Ltd.NCT07623902

Phase 2

A Phase II Randomized Clinical Trial of Venetoclax Combined With FLAG IDA Induction and Consolidation Compared to Standard of Care for Newly Diagnosed Patients With Acute Myeloid Leukemia

This phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induct…

Acute Myeloid LeukemiaMyelodysplastic Syndrome

Estimated

~$75 – $3,000

Actual pay is set by the research site.

OHSU Knight Cancer InstituteNCT07228273

Phase 1

A Randomized, Quadruple-blinded, Placebo-controlled, Single-ascending and Multiple Dose Study to Evaluate the Safety, Local Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Exploratory Clinical Activity of MY006 in Healthy Volunteers and Adolescent and Adult Patients With Peanut Allergy

The goal of this clinical trial is to evaluate the safety, pharmacokinetics, and effectiveness of MY006, a therapy designed to prevent severe or potentially li…

Peanut Allergies

Estimated

~$500 – $10,500

Actual pay is set by the research site.

Mabylon AGNCT07287033

Phase 1

An Open-label, Dose Escalation + Dose Expansion Phase 1 Trial to Determine the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-678 Given Orally to Patients With Chronic Myeloid Leukemia Who Are Resistant or Intolerant to TKI Treatments

The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary e…

Chronic Myelogenous Leukemia

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Shenzhen TargetRx Co., Ltd.NCT06088888

Observational

Comparison of Dental Implant Placement With Simultaneous Sandwich Bone Augmentation vs. Mixed Bone Augmentation: a Randomized Controlled Pilot Study

This study is being done to see which of two common grafting techniques-mixing two different grafting materials or layering two grafting materials-works better…

Peri-implant Bone and Soft Tissues

Estimated

~$10 – $675

Actual pay is set by the research site.

University of California, San FranciscoNCT07832565